Patents by Inventor Jane C. Burns
Jane C. Burns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150377905Abstract: Methods for diagnosis of Kawasaki disease (KD) are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of KD, and to a panel of biomarkers that can be used to distinguish KD from febrile illness.Type: ApplicationFiled: June 24, 2015Publication date: December 31, 2015Inventors: Jane C. Burns, Harvey J. Cohen, Jun Ji, Bo Jin, Bruce Xuefeng Ling, Zhou Tan, Adriana Tremoulet
-
Publication number: 20130316921Abstract: Methods for diagnosis of Kawasaki disease (KD) are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of KD, and more specifically to biomarkers that can be used to distinguish KD from other inflammatory diseases, including infectious illness and acute febrile illness.Type: ApplicationFiled: June 5, 2013Publication date: November 28, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Harvey J. Cohen, Jane C. Burns, John C. Whitin, Bruce Xuefeng Ling, James Schilling
-
Publication number: 20110189698Abstract: A method, kit and device for diagnosing Kawasaki Disease are provided. The invention provides detecting an expression level of at least two Kawasaki Disease diagnostic biomarkers in a biological sample from a patient with a capture agent and diagnosing the patient as having Kawasaki Disease when the expression levels of the at least two diagnostic biomarkers in the patient biological sample are higher than the normal expression levels of the same biomarkers in a biological sample from a control subject. The first Kawasaki Disease diagnostic biomarker disclosed in the present invention is a cardiomyocyte biomarker, and the second Kawasaki Disease diagnostic biomarker is an inflammatory biomarker.Type: ApplicationFiled: February 28, 2011Publication date: August 4, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Jane C. Burns
-
Patent number: 7138562Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: July 18, 2001Date of Patent: November 21, 2006Assignee: Wisconsin Alumni research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 6548740Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: February 11, 2000Date of Patent: April 15, 2003Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W.S. Chan, Jane C. Burns
-
Publication number: 20020129393Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: ApplicationFiled: July 18, 2001Publication date: September 12, 2002Inventors: Robert D. Bremel, Anthony W.S. Chan, Jane C. Burns
-
Patent number: 6291740Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: June 10, 1999Date of Patent: September 18, 2001Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 6080912Abstract: The present invention provides improved methods and compositions for the generation of transgenic non-human animals. The present invention permits the introduction of exogenous nucleic acid sequences into the genome of unfertilized eggs (e.g., pre-maturation oocytes and pre-fertilization oocytes) by microinjection of infectious retrovirus into the perivitelline space of the egg. The methods of the present invention provide an increased efficiency of production of transgenic animals with a reduced rate of generating animals which are mosaic for the presence of the transgene.Type: GrantFiled: March 20, 1997Date of Patent: June 27, 2000Assignee: Wisconsin Alumni Research FoundationInventors: Robert D. Bremel, Anthony W. S. Chan, Jane C. Burns
-
Patent number: 5969211Abstract: A method for introducing foreign nucleic acid sequences into marine mollusks. A pantropic retroviral vector containing a foreign gene sequence is introduced into fertilized mollusk embryos by electroporation. The gene sequence becomes integrated into the host DNA and encodes a functional protein product. This method has implications in the introduction of disease-resistance and growth-accelerating genes into mollusks.Type: GrantFiled: April 18, 1997Date of Patent: October 19, 1999Assignees: Ther Regents of The University of California, The University of ConneticutInventors: Jane C. Burns, Thomas T. Chen
-
Patent number: 5670354Abstract: The present application discloses retrovirus-derived vectors in which the retroviral envelope glycoprotein has been replaced by the G glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10.sup.9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.Type: GrantFiled: June 7, 1995Date of Patent: September 23, 1997Assignee: The Regents of the University of CaliforniaInventors: Jane C. Burns, Jiing-Kuan Yee, Theodore Friedmann
-
Patent number: 5512421Abstract: The present application discloses retrovirus-derived vectors in which the retroviral envelope glycoprotein has been replaced by the G glycoprotein of vesicular stomatitis virus, and the use of these vectors in the transfer of exogenous genes into the cells of a wide variety of non-mammalian organisms. Also disclosed is a method for the generation of retroviral vectors in high titers, wherein a recombinant, stable host cell line is provided which harbors the retroviral vector of interest without envelope protein. High-titer retroviral vector production is initiated by introducing nucleic acid encoding a functional membrane-associated protein into the cell line. The vectors disclosed in the present application can be concentrated by ultracentrifugation to titers greater than 10.sup.9 cfu/ml which are especially useful in human gene therapy trials, and can also infect cells, such as hamster and fish cells, that are ordinarily resistant to infection with vectors containing the retroviral envelope protein.Type: GrantFiled: August 10, 1993Date of Patent: April 30, 1996Assignee: The Regents of the University of CaliforniaInventors: Jane C. Burns, Jiing-Kuan Yee, Theodore Friedmann